Security key
09058V103
BIOCRYST PHARMACEUTICALS INC - COMMON STOCK (BCRX)
CUSIP: 09058V103
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 212,542,303
- Total 13F value
- $1,657,283,429
- Share change
- +12,980,065
- Put/Call ratio
- 72%
- SEC-reported price per share
- $7.80
- Number of holders
- 274
- Value change
- +$104,832,674
- Number of buys
- 133
- Number of sells
- 157
- Shares outstanding
- 249,150,204
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
274
Top holders
10
BCRX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
BIOCRYST PHARMACEUTICALS INC SEC filings
BIOCRYST PHARMACEUTICALS INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 09058V103
Recent filing periods:
Ownership snapshot
Top reported holders of BCRX - BIOCRYST PHARMACEUTICALS INC - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
15/15
Latest evidence
31 Dec 2025
13F
13D/G
3/4/5
Lead comparable stake: 8.4%
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 8.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
8.4%
RA CAPITAL MANAGEMENT, L.P.
7.3%
James E. Flynn
6.8%
Avoro Capital Advisors LLC
4.2%
Charles K. Gayer
0.38%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
8.4%
from 13D/G
|
$161,256,203
21,245,876 shares
|
— | 30 Sep 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
7.3%
|
$116,143,592
15,302,186 shares
|
$0 | 04 Nov 2025 |
| James E. Flynn |
13D/G
Deerfield Mgmt, L.P.
|
6.8%
|
$109,278,420
14,341,000 shares
|
+$16,550,640 | 31 Dec 2025 |
| Avoro Capital Advisors LLC |
13D/G
13F
Company
|
4.2%
|
$71,514,000
8,700,000 shares
|
$0 | 31 Mar 2025 |
| Charles K. Gayer |
3/4/5
President and CCO
|
0.38%
|
$5,248,732
952,583 shares
|
— | 19 Dec 2025 |
| VANGUARD GROUP INC |
13F
Company
|
8.7%
|
$165,392,786
21,790,881 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
274
Shares
212,542,303
Rows available
274
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
282
Q4 2025 holders
274
Holder diff
-8
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend